Introduction: Diabetic retinopathy (DR) is a leading cause of vision loss among working-age population and is related to 1%-5% of cases of blindness worldwide. Anti-VEGF therapy is an effective tool in the management of DME. The purpose of this study was to assess the effectiveness of intravitreal injection of Bevacizumab in the treatment of DME regarding the improvement of best corrected visual acuity (BCVA) and the reduction of central macular thickness (CMT) in Bashundhara Eye Hospital & Research Institute. Methods: The medical records of patients treated with Bevacizumab due to DME at Bashundhara Eye Hospital & Research Institute, between January, 2018 and March, 2022.After applying inclusion and exclusion criteria, 306 patients (368 eyes) were included in the study. Results: Baseline BCVA was worse than 20/40 (mean 20/80; range 20/300-20/50). Baseline central retinal thickness (CRT) was >275im (mean 450 ± 28.39,um, range 114-1000). Around half of the study population (162, 52.94 %) was injected Bevacizumab more than thrice, and the rest of the patients were injected three times during the study period. After the application of three consecutive Bevacizumab injections, BCVA was improved 20/80 in 139 (46.8%) patients and after the application of more than three injection, mean BCVA was improved 20/60 in 158(53.2%) patients. The mean CMT level of the study population after three consecutive anti-VEGF therapy (n=139) was 280±17.02,um. Mean CMT level of study population after more than three anti-VEGF therapy (n=158) was 250±7.42 pm. 9 (2.94%) patients having uncontrolled DM showed no improvement in CMT level & BCVA after intra-vitreal injection. Conclusions: Intravitreal Bevacizumab injections significantly improve visual acuity and decrease central macular thickness in patients with diabetic macular edema.